We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
UK-based Vectura Group has signed an agreement with Kinaset Therapeutics to develop and commercialise a preclinical inhaled pan-JAK inhibitor for the treatment of severe asthma.